Emcure Pharma to acquire remaining stake in arm Zuventus Healthcare
Pune: Emcure Pharmaceuticals has announced that its
Board of Directors has approved to enter into agreement with minority shareholders of Zuventus
Healthcare Ltd., one of its subsidiaries, to acquire their shareholding.
Following the completion of this
transaction, Zuventus will become a wholly owned subsidiary of Emcure.
The transaction is expected
to close in Q2 FY 2026.
“The domestic market remains a strategic priority for Emcure. This transaction will enable full financial
consolidation of Zuventus and drive long-term value creation for Emcure, through alignment across its
domestic business and unlock synergies,” Emcure stated in a release.
In April, Tillomed Laboratories Limited, a subsidiary of Emcure Pharma and a European pharma company, entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare Limited and its subsidiaries Manx Pharma Ltd and Manx Generics Limited (collectively Manx).
Also in April, Gennova Biopharmaceuticals Ltd., another Emcure subsidiary, announced the advancement of the development of a pathbreaking self-amplifying mRNA (saRNA) vaccine against the deadly Nipah virus. Nipah virus belongs to the Paramyxovirus family. It is one of the deadliest pathogens known to infect humans. So far, Nipah outbreaks have been confined to South and Southeast Asia, but the fruit-bat vector is found in large geographical areas across the globe covering a population of more than 2 billion people.
Read also: Emcure Pharma arm Gennova advances development of Nipah virus vaccine
Established in 1981, Emcure Pharmaceuticals Ltd. is an Indian pharma company headquartered in Pune
engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical
products. Emcure is an R&D
driven company that develops and manufactures a wide range of differentiated pharmaceutical
products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally including Europe and Canada.
Read also: Emcure Pharma Anil Kothiyal to resign as President – India Sales & Marketing
